Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Coeptis Therapeutics Holdings Inc (COEPW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: COEPW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -92.08% | Avg. Invested days 18 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 39294 | Beta -0.59 | 52 Weeks Range 0.01 - 0.05 | Updated Date 02/25/2025 |
52 Weeks Range 0.01 - 0.05 | Updated Date 02/25/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -245.55% | Return on Equity (TTM) -1449.7% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 12704886 |
Shares Outstanding - | Shares Floating 12704886 | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Coeptis Therapeutics Holdings Inc
Company Overview
History and Background
Coeptis Therapeutics Holdings Inc. focuses on developing innovative therapies for cancer. The company was founded with a focus on cancer therapeutics and has evolved through strategic acquisitions and partnerships.
Core Business Areas
- Cancer Therapeutics: Developing and commercializing targeted therapies for various types of cancer, including cell therapies and immunotherapies.
Leadership and Structure
Information regarding the specific leadership team and detailed organizational structure can be found on the Coeptis Therapeutics Holdings Inc. website and SEC filings.
Top Products and Market Share
Key Offerings
- CD38-GEAR-NK cell therapy: A cell therapy targeting CD38-expressing cancers. Currently in preclinical and early clinical development. Competitors include companies developing similar cell therapies, such as those targeting CD38 with CAR-T or other NK cell approaches.
- Consensi: A pharmaceutical asset acquired from TRxADE HEALTH. Competitors include companies that also develops and sells pharmaceutical assets.
Market Dynamics
Industry Overview
The cancer therapeutics market is large and growing, driven by an aging population and advances in cancer biology and treatment. It includes immunotherapies, targeted therapies, cell therapies, and traditional chemotherapy.
Positioning
Coeptis Therapeutics Holdings Inc. aims to occupy a niche within the cancer therapeutics market through its innovative therapies. Their position depends on successful clinical trials and regulatory approval.
Total Addressable Market (TAM)
The global cancer therapeutics market is projected to reach hundreds of billions of dollars. Coeptis's positioning depends on the success of its specific therapies and its ability to capture a share of relevant subsegments, such as cell therapies for specific cancers.
Upturn SWOT Analysis
Strengths
- Innovative therapy platform
- Experienced management team
- Strong intellectual property portfolio
Weaknesses
- Limited financial resources
- Dependence on clinical trial outcomes
- Early stage of development
Opportunities
- Partnerships with larger pharmaceutical companies
- FDA approval of key therapies
- Expansion into new markets
Threats
- Competition from established players
- Regulatory hurdles
- Clinical trial failures
Competitors and Market Share
Key Competitors
- JNJ
- GILD
- BMY
Competitive Landscape
Coeptis Therapeutics Holdings Inc. faces intense competition from larger pharmaceutical companies with greater resources. Its success depends on differentiating its therapies and securing strategic partnerships.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited as the company is in the early stages of development.
Future Projections: Future growth depends on clinical trial outcomes, regulatory approvals, and commercialization efforts. Analyst estimates can be obtained from financial data providers.
Recent Initiatives: Recent initiatives include advancing clinical trials, securing partnerships, and expanding the product pipeline.
Summary
Coeptis Therapeutics is an early-stage biotech company focusing on innovative cancer therapies. Its strengths lie in its unique technology platform and experienced team, but it faces challenges typical of small biotechs, including funding and regulatory hurdles. Success hinges on favorable clinical trial results and effective commercialization strategies. Investors should closely monitor its financial position and progress in clinical development.
Similar Companies
- AGEN
- NK
- CRBU
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Market Research Reports
- Financial News Outlets
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share data is approximate and may vary based on the source and methodology.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Coeptis Therapeutics Holdings Inc
Exchange NASDAQ | Headquaters Wexford, PA, United States | ||
IPO Launch date 2020-12-17 | Co-Founder, Chairman, CEO & Pres Mr. David Mehalick | ||
Sector Healthcare | Industry Biotechnology | Full time employees 4 | Website https://coeptispharma.com |
Full time employees 4 | Website https://coeptispharma.com | ||
Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics Holdings, Inc. is headquartered in Wexford, Pennsylvania.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.